Please note that tofacitinib is not approved for the treatment of psoriasis. XELJANZ (tofacitinib citrate) 5 mg tablets are indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). XELJANZ may be used alone or in combination with methotrexate or other non-biologic, disease-modifying antirheumatic drugs (DMARDs). Use of XELJANZ in combination with biologic DMARDs or potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended. Please visit the direct link to the full prescribing information for XELJANZ, including boxed warning and Medication Guide: http://labeling.pfizer.com/ShowLabeling.aspx?id=959.
Related Articles
Changing Our Thinking on Osteoarthritis
It’s time we changed our thinking on osteoarthritis
Foot Pain a Burden for Rheumatology Patients
Researchers say it may even correlate with back, hip, and knee pain
Standing on a Hidden Burden: The Oft-Overlooked Problem of Foot and Ankle Osteoarthritis
The high prevalence and significant burden of osteoarthritis (OA) are well known. But it’s becoming apparent that OA research efforts don’t necessarily match disease prevalence or disability. The International Foot and Ankle Osteoarthritis Consortium (IFOAC) is an international organization of volunteers that seeks to highlight a major and often overlooked problem in OA research—foot and…
Was Gout Rampant Among the Romans?
Lead in wine consumed by Romans may have contributed to a high incidence of gout among aristocrats of the Roman Empire